Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Top Analyst Reports for Eli Lilly, Exxon Mobil & Costco
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...
Wedge Capital Management L L P NC Lowers Stake in Eli Lilly and Company (NYSE:LLY)
Wedge Capital Management L L P NC decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 26.0% ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Why Is Cliff Asness Bullish On Eli Lilly and Company (LLY)?
We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...
Eli Lilly's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...
Eli Lilly and Company: Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...